{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:08:32Z","timestamp":1790345312135,"version":"4.1.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11882-024-01187-1","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T08:39:59Z","timestamp":1732610399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Olfactory Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Effect of Treatment with Emphasis on Biological Therapy"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5437-3005","authenticated-orcid":false,"given":"Josje Janna","family":"Otten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4852-229X","authenticated-orcid":false,"given":"Wytske Johanna","family":"Fokkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1734-2632","authenticated-orcid":false,"given":"Sietze","family":"Reitsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"issue":"5","key":"1187_CR1","first-page":"430","volume":"58","author":"D Borsetto","year":"2020","unstructured":"Borsetto D, et al. Self-reported alteration of sense of smell or taste in patients with COVID-19: a systematic review and meta-analysis on 3563 patients. Rhinology. 2020;58(5):430\u20136. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32626853.","journal-title":"Rhinology"},{"key":"1187_CR2","doi-asserted-by":"crossref","unstructured":"Hopkins C, Surda P. and N. Kumar Presentation of new onset anosmia during the COVID-19 pandemic Rhinology 2020 58 (3) 295\u20138 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32277751","DOI":"10.4193\/Rhin20.116"},{"issue":"33","key":"1187_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin22.483","volume":"61","author":"KL Whitcroft","year":"2023","unstructured":"Whitcroft KL, et al. Position paper on olfactory dysfunction: 2023. Rhinology. 2023;61(33):1\u2013108. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37454287.","journal-title":"Rhinology"},{"key":"1187_CR4","doi-asserted-by":"crossref","unstructured":"Maniaci A, Lechien JR, Vaira LA. and L. La Via taste and Smell disorders: a critical look at olfactory and gustatory dysfunction life (Basel) 2024 14 (3) https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38541627","DOI":"10.3390\/life14030301"},{"key":"1187_CR5","doi-asserted-by":"crossref","unstructured":"Yang J. and J. M. Pinto the epidemiology of olfactory disorders Curr Otorhinolaryngol Rep 2016 4 (2) 130\u201341 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30613439","DOI":"10.1007\/s40136-016-0120-6"},{"key":"1187_CR6","doi-asserted-by":"crossref","unstructured":"Mullol J, et al. Furthering the understanding of olfaction, prevalence of loss of smell and risk factors: a population-based survey (OLFACAT study). BMJ Open. 2012;2(6). https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23135536.","DOI":"10.1136\/bmjopen-2012-001256"},{"issue":"3","key":"1187_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s11882-004-0031-3","volume":"4","author":"P Dalton","year":"2004","unstructured":"Dalton P. Olfaction and anosmia in rhinosinusitis. Curr Allergy Asthma Rep. 2004;4(3):230\u20136. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15056406.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"2","key":"1187_CR8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jaci.2022.10.010","volume":"151","author":"X Wang","year":"2023","unstructured":"Wang X, et al. Endotypes of chronic rhinosinusitis based on inflammatory and remodeling factors. J Allergy Clin Immunol. 2023;151(2):458\u201368. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36272582.","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl S29","key":"1187_CR9","first-page":"1","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens WJ, et al. European position paper on Rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1\u2013464. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32077450.","journal-title":"Rhinology"},{"key":"1187_CR10","doi-asserted-by":"crossref","unstructured":"Fokkens WJ et al. EPOS\/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with nasal polyps 2023 Rhinology 2023 61 (3) 194\u2013202 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36999780","DOI":"10.4193\/Rhin22.489"},{"key":"1187_CR11","doi-asserted-by":"crossref","unstructured":"Lee L, Luke L, Boak D. and C. Philpott Impact of olfactory disorders on personal safety and well-being: a cross-sectional observational study Eur Arch Otorhinolaryngol 2024 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38396298","DOI":"10.22541\/au.168900024.42110173\/v1"},{"key":"1187_CR12","doi-asserted-by":"crossref","unstructured":"Stevens WW et al. Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis J Allergy Clin Immunol Pract 2019 7 (8) 2812\u20132820 e3 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31128376","DOI":"10.1016\/j.jaip.2019.05.009"},{"key":"1187_CR13","doi-asserted-by":"crossref","unstructured":"Ahmed OG. and N. R. Rowan Olfactory Dysfunction and chronic Rhinosinusitis Immunol Allergy Clin North am 2020 40 (2) 223\u201332 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32278447","DOI":"10.1016\/j.iac.2019.12.013"},{"key":"1187_CR14","doi-asserted-by":"crossref","unstructured":"Qureshi HA. and A. P. Lane Olfaction now and in the future in CRSwNP. Am J Rhinol Allergy 2023 37 (2) 168\u201374 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36848279","DOI":"10.1177\/19458924231153485"},{"key":"1187_CR15","doi-asserted-by":"crossref","unstructured":"Macchi A et al. Sense of smell in chronic rhinosinusitis: a multicentric study on 811 patients Front Allergy 2023 4 1083964 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37152304","DOI":"10.3389\/falgy.2023.1083964"},{"key":"1187_CR16","doi-asserted-by":"crossref","unstructured":"Hummel T, Kobal G, Gudziol H. and A. Mackay-Sim Normative data for the Sniffin\u2019 Sticks including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects Eur Arch Otorhinolaryngol 2007 264 (3) 237\u201343 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17021776","DOI":"10.1007\/s00405-006-0173-0"},{"key":"1187_CR17","doi-asserted-by":"crossref","unstructured":"Brumm MC et al. Updated percentiles for the University of Pennsylvania Smell Identification Test in adults 50 years of age and older Neurology 2023 100 (16) e1691\u2013701 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36849448","DOI":"10.1212\/WNL.0000000000207077"},{"key":"1187_CR18","doi-asserted-by":"crossref","unstructured":"Ogihara H, Kobayashi M, Nishida K, Kitano M. and K. Takeuchi Applicability of the cross-culturally modified University of Pennsylvania Smell Identification Test in a Japanese population. Am J Rhinol Allergy 2011 25 (6) 404\u201310 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22185745","DOI":"10.2500\/ajra.2011.25.3658"},{"issue":"1","key":"1187_CR19","first-page":"28","volume":"5","author":"RS Jiang","year":"2014","unstructured":"Jiang RS, Kuo LT, Wu SH, Su MC. Liang Validation of the applicability of the traditional Chinese version of the University of Pennsylvania Smell Identification Test in patients with chronic rhinosinusitis Allergy Rhinol. (Providence). 2014;5(1):28\u201335. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25199144.","journal-title":"(Providence)"},{"issue":"5","key":"1187_CR20","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.2500\/ajra.2015.29.4212","volume":"29","author":"A Altundag","year":"2015","unstructured":"Altundag A, et al. Cross-culturally modified University of Pennsylvania Smell Identification Test for a Turkish population. Am J Rhinol Allergy. 2015;29(5):e138\u201341. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26358338.","journal-title":"Am J Rhinol Allergy"},{"key":"1187_CR21","doi-asserted-by":"crossref","unstructured":"Alsaleh S et al. Cross-cultural modification of the University of Pennsylvania smell identification test for the Saudi Arabian population: validation and normative values. Saudi Med J 2024 45 (1) 79\u201385 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38220245","DOI":"10.15537\/smj.2024.45.1.20230422"},{"key":"1187_CR22","doi-asserted-by":"crossref","unstructured":"Fornazieri MA, Doty RL, Santos CA, Pinna Fde R, Bezerra TF, Voegels RL. (Sao Paulo). 2013;68(1):65\u20138. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23420159. A new cultural adaptation of the University of Pennsylvania Smell Identification Test Clinics.","DOI":"10.6061\/clinics\/2013(01)OA10"},{"issue":"1","key":"1187_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/coa.12212","volume":"39","author":"M Picillo","year":"2014","unstructured":"Picillo M, et al. Validation of an Italian version of the 40-item University of Pennsylvania Smell Identification Test that is physician administered: our experience on one hundred and thirty-eight healthy subjects. Clin Otolaryngol. 2014;39(1):53\u20137. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24373213.","journal-title":"Clin Otolaryngol"},{"key":"1187_CR24","doi-asserted-by":"crossref","unstructured":"Alobid I, et al. Validation of Visual Analogue Scale for loss of smell as a quick test in chronic rhinosinusitis with nasal polyps. J Investig Allergol Clin Immunol. 2023;0. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37675801.","DOI":"10.18176\/jiaci.0937"},{"key":"1187_CR25","unstructured":"Dietz de Loos DAE, Cornet ME, Hopkins C, Fokkens WJ. and S. Reitsma measuring control of disease in Chronic Rhinosinusitis; assessing the correlation between SinoNasal Outcome Test-22 and Visual Analogue Scale item scores Rhinology 2023 61 (1) 39\u201346 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36240497"},{"issue":"5","key":"1187_CR26","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/all.15982","volume":"79","author":"PW Hellings","year":"2024","unstructured":"Hellings PW, et al. EUFOREA\/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care. Allergy. 2024;79(5):1123\u201333. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38108602.","journal-title":"Allergy"},{"key":"1187_CR27","unstructured":"Orlandi RR et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021 Int Forum Allergy Rhinol 2021 11 (3) 213\u2013739 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33236525"},{"key":"1187_CR28","doi-asserted-by":"crossref","unstructured":"Mygind N et al. Mode of action of intranasal corticosteroids. J Allergy Clin Immunol 2001 108 (1 Suppl) S16-25 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11449202","DOI":"10.1067\/mai.2001.115561"},{"key":"1187_CR29","doi-asserted-by":"crossref","unstructured":"Bognanni A et al. Topical corticosteroids for chronic rhinosinusitis with nasal polyposis: GRADE systematic review and network meta-analysis. J Allergy Clin Immunol 2022 150 (6) 1447\u201359 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35970310","DOI":"10.1016\/j.jaci.2022.07.023"},{"key":"1187_CR30","doi-asserted-by":"crossref","unstructured":"Chong LY, Head K, Hopkins C, Philpott C, Schilder AG. and M. J. Burton Intranasal steroids versus placebo or no intervention for chronic rhinosinusitis. Cochrane Database Syst Rev 2016 4 (4) CD011996 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27115217","DOI":"10.1002\/14651858.CD011996.pub2"},{"key":"1187_CR31","doi-asserted-by":"crossref","unstructured":"Wu D, Huang T. and Y. Wei effects of Fluticasone Exhalation Delivery System in patients with chronic Rhinosinusitis with nasal polyps: a systematic review. Am J Rhinol Allergy 2022 36 (2) 176\u201384 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34342516","DOI":"10.1177\/19458924211033214"},{"key":"1187_CR32","doi-asserted-by":"crossref","unstructured":"Calvo-Henriquez C, et al. The role of corticosteroid nasal irrigations in the management of Chronic Rhinosinusitis: a state-of-the-art systematic review. J Clin Med. 2023;12(10). https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37240711.","DOI":"10.3390\/jcm12103605"},{"key":"1187_CR33","doi-asserted-by":"crossref","unstructured":"Van Gerven L, Langdon C, Cordero A, Cardelus S, Mullol J. and I. Alobid lack of long-term add-on effect by montelukast in postoperative chronic rhinosinusitis patients with nasal polyps laryngoscope 2018 128 (8) 1743\u201351 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29114894","DOI":"10.1002\/lary.26989"},{"key":"1187_CR34","doi-asserted-by":"crossref","unstructured":"Kern RC et al. A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps. Int Forum Allergy Rhinol 2018 8 (4) 471\u201381 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29350840","DOI":"10.1002\/alr.22084"},{"key":"1187_CR35","doi-asserted-by":"crossref","unstructured":"Chong LY, Head K, Hopkins C, Philpott C, Burton MJ. and A. G. Schilder different types of intranasal steroids for chronic rhinosinusitis. Cochrane Database Syst Rev 2016 4 (4) CD011993 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27115215","DOI":"10.1002\/14651858.CD011993.pub2"},{"issue":"12","key":"1187_CR36","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/alr.21373","volume":"4","author":"SM Banglawala","year":"2014","unstructured":"Banglawala SM, Oyer SL, Lohia S, Psaltis AJ, Soler ZM. Schlosser olfactory outcomes in chronic rhinosinusitis with nasal polyposis after medical treatments: a systematic review and meta-analysis. Int Forum Allergy Rhinol. 2014;4(12):986\u201394. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25400017.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"5","key":"1187_CR37","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.jaci.2010.02.020","volume":"125","author":"T Van Zele","year":"2010","unstructured":"Van Zele T, et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010;125(5):1069\u201376. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20451040.","journal-title":"J Allergy Clin Immunol"},{"key":"1187_CR38","unstructured":"Yasir M, Goyal A, Sonthalia S. Corticosteroid adverse effects, in StatPearls. Treasure Island (FL); 2024."},{"key":"1187_CR39","doi-asserted-by":"crossref","unstructured":"Hox V et al. Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper Clin Transl Allergy 2020 10 1 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31908763","DOI":"10.1186\/s13601-019-0303-6"},{"key":"1187_CR40","doi-asserted-by":"crossref","unstructured":"Zhao R, Chen K. and Y. Tang olfactory changes after endoscopic sinus surgery for chronic rhinosinusitis: a meta-analysis Clin Otolaryngol 2021 46 (1) 41\u201351 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32865350","DOI":"10.1111\/coa.13639"},{"key":"1187_CR41","doi-asserted-by":"crossref","unstructured":"Prasad S, Fong E. and E. H. Ooi systematic review of patient-reported outcomes after revision endoscopic sinus surgery. Am J Rhinol Allergy 2017 31 (4) 248\u201355 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28716176","DOI":"10.2500\/ajra.2017.31.4446"},{"key":"1187_CR42","doi-asserted-by":"crossref","unstructured":"Rimmer J, Fokkens W, Chong LY. and C. Hopkins Surgical versus medical interventions for chronic rhinosinusitis with nasal polyps. Cochrane Database Syst Rev 2014 2014 (12) CD006991 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25437000","DOI":"10.1002\/14651858.CD006991.pub2"},{"key":"1187_CR43","doi-asserted-by":"crossref","unstructured":"Novarria GA, Vultaggio F, Saginario V, Felisati G. and A. M. Saibene Efficacy and safety of middle turbinate surgery: a systematic review. Eur Arch Otorhinolaryngol 2024 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38992192","DOI":"10.1007\/s00405-024-08825-4"},{"key":"1187_CR44","doi-asserted-by":"crossref","unstructured":"Lourijsen ES et al. Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial. Lancet Respir Med 2022 10 (4) 337\u201346 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35012708","DOI":"10.1016\/S2213-2600(21)00457-4"},{"key":"1187_CR45","doi-asserted-by":"crossref","unstructured":"Haxel BR, Boessert P, Weyer-Elberich V. and K. Fruth Course of olfaction after sinus surgery for chronic rhinosinusitis laryngoscope Investig Otolaryngol 2017 2 (5) 269\u201375 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29094070","DOI":"10.1002\/lio2.109"},{"key":"1187_CR46","doi-asserted-by":"crossref","unstructured":"Calus L et al. Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis. Clin Transl Allergy 2019 9 30 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31249662","DOI":"10.1186\/s13601-019-0269-4"},{"key":"1187_CR47","unstructured":"Arancibia C, Langdon C, Mullol J. and I. Alobid twelve-year long-term postoperative outcomes in patients with chronic rhinosinusitis with nasal polyps Rhinology 2022 60 (4) 261\u20139 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35934318"},{"key":"1187_CR48","doi-asserted-by":"crossref","unstructured":"Rodriguez-Van Strahlen C, Arancibia C, Calvo-Henriquez C, Mullol J. and I. Alobid systematic review of Long Term Sinonasal outcomes in CRSwNP after endoscopic sinus surgery: a call for unified and standardized criteria and terms Curr Allergy Asthma Rep 2024 24 (8) 443\u201356 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38913122","DOI":"10.1007\/s11882-024-01154-w"},{"key":"1187_CR49","doi-asserted-by":"crossref","unstructured":"Hsu CY, Wang YP, Shen PH, Weitzel EK, Lai JT. and P. J. Wormald Objective olfactory outcomes after revision endoscopic sinus surgery. Am J Rhinol Allergy 2013 27 (4) e96\u2013100 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23883800","DOI":"10.2500\/ajra.2013.27.3939"},{"key":"1187_CR50","doi-asserted-by":"crossref","unstructured":"Mullol J et al. Olfactory outcomes with Dupilumab in Chronic Rhinosinusitis with nasal polyps J Allergy Clin Immunol Pract 2022 10 (4) 1086\u201395 e5 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34628065","DOI":"10.1016\/j.jaip.2021.09.037"},{"key":"1187_CR51","unstructured":"Bachert C et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials Lancet 2019 394 (10209) 1638\u201350 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31543428"},{"key":"1187_CR52","unstructured":"Lee SE et al. The relationship of sinus opacification, olfaction and dupilumab efficacy in patients with CRSwNP Rhinology 2023 61 (6) 531\u201340 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37453138"},{"key":"1187_CR53","doi-asserted-by":"crossref","unstructured":"Albrecht T, Sailer MM, Capitani F, van Schaik C, Lowenheim H. and S. Becker Real-World evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1 year of therapy. World Allergy Organ J 2023 16 (5) 100780 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37234094","DOI":"10.1016\/j.waojou.2023.100780"},{"key":"1187_CR54","doi-asserted-by":"crossref","unstructured":"Galletti C et al. Dupilumab in chronic rhinosinusitis with nasal polyps: real life data in a multicentric sicilian experience. Am J Otolaryngol 2024 45 (1) 104106 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37948824","DOI":"10.1016\/j.amjoto.2023.104106"},{"key":"1187_CR55","doi-asserted-by":"crossref","unstructured":"van der Lans RJL, Fokkens WJ, Adriaensen G, Hoven DR, Drubbel JJ. and S. Reitsma Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps Allergy 2022 77 (2) 670\u20134 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34626497","DOI":"10.1111\/all.15134"},{"key":"1187_CR56","doi-asserted-by":"crossref","unstructured":"Gudziol V, Lotsch J, Hahner A, Zahnert T. and T. Hummel Clinical significance of results from olfactory testing laryngoscope 2006 116 (10) 1858\u201363 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17003712","DOI":"10.1097\/01.mlg.0000234915.51189.cb"},{"key":"1187_CR57","doi-asserted-by":"crossref","unstructured":"van der Lans RJL et al. Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months Allergy 2023 78 (10) 2684\u201397 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37394895","DOI":"10.1111\/all.15796"},{"key":"1187_CR58","unstructured":"Otten JJ et al. Steroid responsiveness predicts olfactory function recovery in dupilumab treated CRSwNP Rhinology 2024 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38775362"},{"key":"1187_CR59","doi-asserted-by":"crossref","unstructured":"Cantone E et al. Olfaction recovery following Dupilumab is Independent of Nasal Polyp reduction in CRSwNP. J Pers Med 2022 12 (8) https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35893310","DOI":"10.3390\/jpm12081215"},{"key":"1187_CR60","doi-asserted-by":"crossref","unstructured":"Wu Q et al. Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials BMJ Open 2021 11 (9) e047344 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34479933","DOI":"10.1136\/bmjopen-2020-047344"},{"key":"1187_CR61","doi-asserted-by":"crossref","unstructured":"Gevaert P et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 2020 146 (3) 595\u2013605 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32524991","DOI":"10.1016\/j.jaci.2020.05.032"},{"key":"1187_CR62","doi-asserted-by":"crossref","unstructured":"Mahadev A, Kallogjeri D. and J. F. Piccirillo Validation of Minimal clinically important difference (MCID) for University of Pennsylvania Smell Identification Test (UPSIT). Am J Rhinol Allergy 2024 38 (2) 123\u201332 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38055971","DOI":"10.1177\/19458924231218037"},{"key":"1187_CR63","doi-asserted-by":"crossref","unstructured":"Gevaert P et al. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. J Allergy Clin Immunol 2022 149 (3) 957\u201365 e3 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34530020","DOI":"10.1016\/j.jaci.2021.07.045"},{"key":"1187_CR64","doi-asserted-by":"crossref","unstructured":"T. S. Tat Omalizumab is effective in nasal polyposis with or without asthma, a real-life study. World Allergy Organ J 2022 15 (8) 100670 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36017064","DOI":"10.1016\/j.waojou.2022.100670"},{"key":"1187_CR65","doi-asserted-by":"crossref","unstructured":"Zheng M et al. Clinical effectiveness and potential predictability of omalizumab in patients with difficult-to-treat chronic rhinosinusitis with nasal polyps and asthma based on the noninvasive markers - a real-life prospective study. World Allergy Organ J 2022 15 (10) 100702 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36254182","DOI":"10.1016\/j.waojou.2022.100702"},{"key":"1187_CR66","unstructured":"Han JK et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet. Respir Med 2021 9 (10) 1141\u201353 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33872587"},{"key":"1187_CR67","doi-asserted-by":"crossref","unstructured":"Gallo S et al. Mepolizumab improves outcomes of chronic rhinosinusitis with nasal polyps in severe asthmatic patients: a Multicentric Real-Life Study. J Pers Med 2022 12 (8) https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36013253","DOI":"10.3390\/jpm12081304"},{"key":"1187_CR68","doi-asserted-by":"crossref","unstructured":"Dominguez-Sosa MS et al. Real-life effectiveness of Mepolizumab in Refractory Chronic Rhinosinusitis with nasal polyps Biomedicines 2023 11 (2) https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36831021","DOI":"10.3390\/biomedicines11020485"},{"key":"1187_CR69","doi-asserted-by":"crossref","unstructured":"Forster-Ruhrmann U et al. A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyposis treated with T2-biologics. World Allergy Organ J 2023 16 (2) 100746 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36852411","DOI":"10.1016\/j.waojou.2023.100746"},{"key":"1187_CR70","unstructured":"Mullol J et al. Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE Rhinology 2024 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38217844"},{"key":"1187_CR71","doi-asserted-by":"crossref","unstructured":"Kariyawasam HH et al. Biologic treatment for severe chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis Rhinology 2023 61 (2) 98\u2013107 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37023247","DOI":"10.4193\/Rhin22.412"},{"key":"1187_CR72","doi-asserted-by":"crossref","unstructured":"Wu Q et al. Which is the best biologic for nasal polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis. Int Arch Allergy Immunol 2022 183 (3) 279\u201388 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34607329","DOI":"10.1159\/000519228"},{"key":"1187_CR73","doi-asserted-by":"crossref","unstructured":"Agache I et al. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines Allergy 2021 76 (8) 2337\u201353 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33683704","DOI":"10.1111\/all.14809"},{"key":"1187_CR74","doi-asserted-by":"crossref","unstructured":"Papacharalampous GX, Constantinidis J, Fotiadis G, Zhang N, Bachert C. and M. Katotomichelakis Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents\u2019 efficacy. Int Forum Allergy Rhinol 2024 14 (1) 96\u2013109 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37394893","DOI":"10.1002\/alr.23234"},{"key":"1187_CR75","doi-asserted-by":"crossref","unstructured":"Peters AT et al. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with nasal polyps J Allergy Clin Immunol Pract 2021 9 (6) 2461\u201371 e5 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33548517","DOI":"10.1016\/j.jaip.2021.01.031"},{"key":"1187_CR76","doi-asserted-by":"crossref","unstructured":"Lipworth BJ. and R. Chan the Choice of Biologics in patients with severe chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract 2021 9 (12) 4235\u20138 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34332173","DOI":"10.1016\/j.jaip.2021.07.023"},{"key":"1187_CR77","doi-asserted-by":"crossref","unstructured":"Oykhman P, Paramo FA, Bousquet J, Kennedy DW, Brignardello-Petersen R. and D. K. Chu comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis. J Allergy Clin Immunol 2022 149 (4) 1286\u201395 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34543652","DOI":"10.1016\/j.jaci.2021.09.009"},{"key":"1187_CR78","unstructured":"Philpott C et al. Developing a core outcome set for clinical trials in olfactory disorders: a COMET initiative Rhinology 2023 61 (4) 312\u20139 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37243690"},{"key":"1187_CR79","doi-asserted-by":"crossref","unstructured":"Bachert C et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol 2022 149 (4) 1309\u201317 e12 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34599979","DOI":"10.1016\/j.jaci.2021.08.030"},{"key":"1187_CR80","unstructured":"Efficacy. and Safety of Depemokimab (GSK3511294) in participants with chronic Rhinosinusitis with nasal polyps (ANCHOR-2) (ANCHOR-2). https:\/\/clinicaltrials.gov\/study\/NCT05281523 (accessed 25-07-2024."},{"key":"1187_CR81","doi-asserted-by":"crossref","unstructured":"Smith TD. and K. P. Bhatnagar Anatomy of the olfactory system. Handb Clin Neurol 2019 164 17\u201328 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31604545","DOI":"10.1016\/B978-0-444-63855-7.00002-2"},{"key":"1187_CR82","doi-asserted-by":"crossref","unstructured":"Finlay JB et al. Persistent post-COVID-19 smell loss is associated with inflammatory infiltration and altered olfactory epithelial gene expression bioRxiv 2022 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35478953","DOI":"10.1101\/2022.04.17.488474"},{"key":"1187_CR83","doi-asserted-by":"crossref","unstructured":"Briner HR, Simmen D. and N. Jones impaired sense of smell in patients with nasal surgery clin Otolaryngol Allied Sci 2003 28 (5) 417\u20139 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12969343","DOI":"10.1046\/j.1365-2273.2003.00735.x"},{"key":"1187_CR84","doi-asserted-by":"crossref","unstructured":"Seys SF et al. Real-life assessment of chronic rhinosinusitis patients using mobile technology: the mySinusitisCoach project by EUFOREA Allergy 2020 75 (11) 2867\u201378 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32424899","DOI":"10.1111\/all.14408"},{"key":"1187_CR85","unstructured":"Nettis E et al. Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life. Clin Mol Allergy 2022 20 (1) 6 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35590407"},{"key":"1187_CR86","doi-asserted-by":"crossref","unstructured":"Ottaviano G et al. Effectiveness of Dupilumab in the treatment of patients with uncontrolled severe CRSwNP: a real-life observational study in naive and post-surgical patients. J Pers Med 2022 12 (9) https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36143311","DOI":"10.3390\/jpm12091526"},{"key":"1187_CR87","doi-asserted-by":"crossref","unstructured":"De Corso E et al. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational phase IV real-life study (DUPIREAL) allergy 2023 78 (10) 2669\u201383 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37203259","DOI":"10.1111\/all.15772"},{"key":"1187_CR88","doi-asserted-by":"crossref","unstructured":"Campion NJ et al. The real life efficacy of dupilumab is independent of initial polyp size and concomitant steroids in CRSwNP. J Otolaryngol Head Neck Surg 2023 52 (1) 56 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37674253","DOI":"10.1186\/s40463-023-00663-4"},{"key":"1187_CR89","doi-asserted-by":"crossref","unstructured":"Kiricsi A et al. Real-life effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps. Results from eight Hungarian centres with 12-month follow-up Rhinology 2024 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38848046","DOI":"10.4193\/Rhin23.278"},{"key":"1187_CR90","doi-asserted-by":"crossref","unstructured":"Meier EC, Schmid-Grendelmeier P, Steiner UC. and M. B. Soyka Real-Life experience of monoclonal antibody treatments in chronic rhinosinusitis with nasal polyposis int Arch Allergy Immunol 2021 182 (8) 736\u201343 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33756474","DOI":"10.1159\/000514262"},{"key":"1187_CR91","doi-asserted-by":"crossref","unstructured":"Viciana MG. In: Eusebio I, editor. Real-life effectiveness of mepolizumab in patients with chronic rhinosinusitis with nasal polyps. Volume 153. Ed., ed: The Journal of Allergy and Clinical Immunology; 2024.","DOI":"10.1016\/j.jaci.2023.11.675"},{"issue":"4","key":"1187_CR92","doi-asserted-by":"publisher","first-page":"104329","DOI":"10.1016\/j.amjoto.2024.104329","volume":"45","author":"C Galletti","year":"2024","unstructured":"Galletti C, et al. Effectiveness and safety profile of mepolizumab in chronic rhinosinusitis with nasal polyps: real life data in a tertiary care. Am J Otolaryngol. 2024;45(4):104329. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38696895.","journal-title":"Am J Otolaryngol"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-024-01187-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-024-01187-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-024-01187-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T09:16:13Z","timestamp":1732612573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-024-01187-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1187"],"URL":"https:\/\/doi.org\/10.1007\/s11882-024-01187-1","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"6 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"WF is an advisory board member of and received consulting fees from of Sanofi, GSK, and Dianosic. SR has acted as a consultant and\/or advisory board member for Sanofi, GSK, and Novartis. The department of Otorhinolaryngology and Head\/Neck Surgery of the Amsterdam UMC has received research funding from Sanofi, GSK, and Novartis. JO has acted as a speaker for Sanofi.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"6"}}